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 Osteoarthritis (OA) is a debilitating disease caused by the deterioration of articular 
cartilage and is a leading cause of disability in the United States and worldwide. Much current 
research into improved treatment for this disease is focused on tissue engineering through the 
growth of cartilage sheets made by articular chondrocytes. However, as chondrocytes proliferate 
in vitro, they also lose their ability to produce dense extracellular matrix, a necessary component 
of articular cartilage conferring mechanical strength. SOX9, a transcriptional activator, increases 
type II collagen expression, a key articular cartilage extracellular matrix component. Thus, SOX9 
promotes an articular cartilage phenotype. Therefore, increasing SOX9 expression and activity as 
a transcriptional activator in culture has the potential to improve tissue engineering outcomes. This 
project serves to generate SOX9 promotor-driven secreted luciferase reporter chondrocytes to 
monitor chondrogenic properties temporally and non-destructively for use in high-throughput 
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CHAPTER ONE: INTRODUCTION 
Osteoarthritis 
Osteoarthritis (OA) is a chronic joint condition in which the articular cartilage covering the end of 
bones deteriorates, causing changes in cartilage composition and reduction in structural integrity. 
The response to this deterioration is inflammation, resulting in swelling, pain, and motion 
impairment. OA can be a product of joint overuse causing gradual degradation and usually 
develops with age, particularly in those who are overweight or have jobs that are demanding on 
the joints. It can also develop in younger people after traumatic, sudden injury. Both these sudden 
and overuse injuries cause lesions in the articular cartilage, which become progressively larger 
until the bone is completely exposed. Late stage OA is a serious disability, with extreme pain and 
loss of joint function [1]. Globally, around 303 million people are affected, and OA accounts for 
more than 10% of US national healthcare costs [2, 3]. 
 
Current treatments for OA 
Treatment for osteoarthritis varies as the disease progresses, and often include prescription and 
over-the-counter painkillers, physical therapy or acupuncture, assistive devices such as canes or 
walkers, and eventually surgery such as total knee arthroscopy [4]. Further damage can sometimes 
be mitigated with gait training, weight management and other risk factor reduction. The most 
commonly recommended treatment is a course of non-steroidal anti-inflammatory drugs; however, 
patients only had moderate benefit from this plan [5]. As the disease progresses and pain can no 





total knee arthroplasty (TKA). TKA involves the removal of damaged tissue from the joint and the 
insertion of artificial materials at the bone interface. While this option usually results in reduced 
pain and increased function, one in five patients remain unsatisfied after the surgery. This may be 
due in part to complications arising after surgery which can include infections and periprosthetic 
failure or loosening. Additionally, the inserted prosthetics only last 15 to 20 years, making TKA a 
poor option for younger patients [6].  
 In 2005, osteoarthritis and other rheumatic diseases were the largest cause of reported 
disability in the US, making up 19% of the total [7]. An estimated 26.9 million Americans had 
symptomatic OA in 2008, increased from 21 million in 1995 [8]. The associated costs of OA for 
both medical expenses and lost income for those affected are also significant. For the average 
person diagnosed with OA at age 54, the direct medical costs of their condition total over $19,000 
during their lives [9]. Additionally, people with OA lose $4,835 in income every year as a direct 
cost of their condition, resulting in a total attributable cost of $154.8 billion dollars per year in the 
US alone [10].  With the aging US population, OA disease instances and the associated costs will 
only increase in the coming years, making advancements in treatment options particularly 
impactful. 
 
Tissue Engineering of Cartilage 
Cell-Based Treatment Options 
One cell-based technique for cartilage regeneration which has seen promise is autologous 





are removed from an area of the joint that is low load-bearing. These samples are then expanded 
in culture and re-implanted at the site of the cartilage defect [11]. A second-generation method, 
matrix-assisted autologous chondrocyte implantation (MACI), involves culturing the harvested 
cells on a collagen scaffold before implantation which improves cell distribution [12]. Short-term 
clinical outcomes for ACI are mostly positive, with one 3 year follow up study showing 84% of 
patients had improvements in pain and function while only 6% had graft failure [13]. 
 Sadly, despite some success with ACI, the treatment still faces several difficulties. First, 
while ACI can be useful for treating small defects that may later lead to symptomatic OA, patients 
with OA often have defects much too large for this treatment to be effective [14]. Additionally, 
ACI requires that there be an undamaged area of the joint from which to harvest tissue, a 
requirement people with severe OA may not reach; even if such an area exists, the removal of 
tissue results in the production of an additional lesion [15]. Once grafted, the new tissues do not 
always integrate with the surrounding cartilage, leading to a weak graft that will ultimately fail 
[16]. After implantation, ACI grafts often do not produce hyaline cartilage, but fibrocartilage 
which has much worse mechanical properties [17]. Finally, as the tissue is re-implanted into a joint 
with significant damage and inflammation, it can be a challenge to ensure the grafted tissue 
remains healthy over time [14]. All of these limitations lead to poor long-term results; in a 10 year 
follow up study of patients who had undergone autologous implantation, 25% had one or more of 






Current State of Tissue Engineering in OA 
The transcription factor SOX9 is a necessary factor in the differentiation of chondrocytes. Articular 
chondrocytes arise from mesenchymal stromal cells (MSCs), otherwise known as 
chondroprogenitors. These cells can ultimately differentiate into myoblasts, adipocytes, or 
osteoblasts, as well as chondrocytes. For an MSC to differentiate into a chondrocyte, it must 
express SOX9, a transcription factor which promotes expression of proteins necessary for 
chondrogenesis including type II collagen and aggrecan [19]. SOX9 is expressed in cells 
undergoing mesenchymal condensation, and people with mutated SOX9 have severe skeletal 
deformations, indicating that SOX9 is necessary for appropriate chondrocytic and skeletal 
development [20]. Additionally, studies of mice chimeras have shown that cells lacking SOX9 do 
not contribute to the formation of cartilage [21]. SOX9 was also shown to be necessary for 
chondrogenesis from mouse embryonic fibroblasts, as when expression is silenced through siRNA, 













 Current culture methods for cartilage tissue face several problems, the largest of which is 
the de-differentiation of cells resulting in a reduction of SOX9 and type II collagen production that 
occurs with prolonged monolayer culture. Monolayer culturing of cells is necessary to increase the 
number of cells in order to have enough to form new tissue. While freshly harvested chondrocytes 
initially express high levels of type II collagen and proteoglycans, after serial culture in monolayer 
Figure 1: SOX9 in Chondrogenic Differentiation 
SOX9 activates the transcription of proteins essential to articular 
cartilage extracellular matrix such as aggrecan and type II collagen. 
Differentiation to a chondrocytic line does not occur without this factor. 





the cells stop having this phenotype and switch from their usual cuboidal morphology to a 
fibroblastic elongated and flatter morphology [23]. A 2003 study of human articular chondrocytes 
(HACs) found that after of 21 days in culture and in subsequent serial cultures, the levels of type 
II collagen, a protein necessary for articular cartilage which is activated by transcription factor 
SOX9, dropped dramatically, down to 100-fold less by day 28. Type II collagen is a major 
component of the extracellular matrix that dictates the mechanical strength of cartilage and its loss 
is therefore an indicator of de-differentiation in culture [24]. Further studies have shown that in 
culture, these cells also lose their ability to produce chondromodulin and glycosaminoglycans. 
Proliferation of HACs on tissue culture plastic causes de-differentiation [25]. Immortalized cells 
can show distinct phenotypic differences to primary cells and are a poor representation of the in 
vivo environment. Being able to track the expression of SOX9 non-destructively will allow us to 
optimize culture methods to keep chondrocytes in a chondrogenic state.  
 With the shortcomings of using ACI to repair only small defects, new cell-based tissue 
engineering treatment options to resurface the entire joint are being explored. Tissue engineering 
refers to the production of a biological rather than inorganic material to replace or restore tissues 
or even whole organs [17]. However, like traditional ACI, tissue engineering must surmount the 
problem of the de-differentiation of cells in culture. Research into effective tissue engineering of 
articular cartilage includes questions about cell source, scaffolding, signal molecules for growth 
induction, and mechanical stimulation methods. The cell type chosen must be accessible and 
numerous while still maintaining chondrocytic properties, and the environmental factors must 
encourage production of SOX9, type II collagen, and other chondrocytic marker proteins to combat 





quantity of cells with appropriate chondrogenic properties to make an engineered cartilage that is 
an effective replacement for damaged tissues [26]. To do this, these factors must be adjusted by 
quantifying how they affect the mechanical and molecular properties of the cell.  
Destructive Methods of Tissue Visualization 
Genetic, biochemical, and mechanical quantification methods have been used to help determine 
what conditions are best for the growth of cartilage in culture. The effect of variables such as 
scaffolds [27], oxygen tension [28], and growth on extracellular matrix [29] among others on the 
properties of cultured chondrocytes have all been tested and used to improve culture methods. 
These variables’ effects are commonly determined using terminal destructive assays on the tissues 
to quantify factors like the type II collagen and glycosaminoglycan (GAG) content, or mechanical 
properties like shear and aggregate modulus, or the tissue’s deformation under load. GAG location 
can be determined through staining and histological evaluation, while its amount can be quantified 
through biochemical assays. The expression of proteins like type II collagen can be determined by 
ELISA, while gene expression can be determined by evaluating the mRNA content of the cell [29]. 
Mechanical properties of cartilage tissue are commonly evaluated by subjecting a punch sample 
of a cartilage sheet to an indentation test [27]. 
 While the terminal, destructive methods listed above provide useful information about a 
tissue’s properties, they have several drawbacks. Firstly, terminal methods only provide 
information about the result and whatever times are chosen to be sampled rather than continuous 
temporal information. This prevents one from making time related insights, which can be critical 
as properties may change dramatically as the cells proliferate and differentiate. Additionally, 





This is a problem when using these assaying methods to determine sample quality, as these 
properties may vary widely from sample to sample. Finally, these methods are time consuming 
and do not easily allow for high-throughput screening of many culture conditions at once [30]. 
Therefore, there is a need to develop non-destructive methods that are easy to quantify and can be 
used to track changes in properties temporally to advance cartilage cell culture techniques for tissue 
engineering.  
 
SOX9 as an Indicator for Cartilage Success 
Overview of Cartilage and Chondrocytes 
Cartilage develops as an embryonic tissue that is the basis for adult skeletal elements. Much 
embryonic cartilage ultimately calcifies into bone, but some cartilage remains into adulthood, 
including that of the trachea, nose, ear, and articular cartilage in the joints. Articular cartilage is of 
particular interest as it is subjected to stresses in the joint and is therefore prone to morbidities such 
as osteoarthritis [31]. Articular cartilage is an avascular tissue made up of chondrocytes, a 
specialized cell type, and the extra-cellular matrix (ECM) those cells produced structured in 
several layers. These layers provide protection from varying stresses; the outer layer, called the 
tangential zone, is a very thin layer that protects from shear stresses. Beneath this layer is the 
transitional zone, which provides some resistance to compressive forces, and the deep zone that 
provides the most compressive resistance. These zones differ in the organization and composition 
of the extracellular matrix, giving them their unique properties. Finally, a layer of calcified ECM 






The one cell type in cartilage, the chondrocyte, functions to build and maintain the ECM which 
gives cartilage its mechanical properties. These cells are extremely sparse in adult cartilage, 
making up only 2% of the volume of cartilage tissue. As cartilage is avascular, the cells rely on 
diffusion and metabolize primarily anaerobically. The dense ECM produced by the chondrocytes 
prevents cell movement throughout the tissue, contributing to the inability of cartilage tissue to 
successfully repair itself once damaged [32]. While there is little cell-to-cell signaling of 
chondrocytes due to their isolated nature, these cells can respond to mechanical stimuli as well as 
growth factors and cytokines by remodeling the ECM surrounding them. A chondrocyte’s ECM 
Figure 2: Articular Cartilage Composition 
The histology section on the left shows a safranin-O stained piece of 
articular cartilage. Red stain indicates presence of GAG. The green stain 
clearly shows the tidemark where cartilage becomes calcified and 
becomes subchondral bone. The cartoon on the right shows the different 
areas of the tissue. At the top, chondrocytes are more flattened, becoming 
rounded as you go deeper into the tissue before becoming columnar in 





is made up predominantly of collagens and proteoglycans; type II collagen is the predominant 
collagen while aggrecan is the predominant proteoglycan [32].  
 There are several cell lines often used as an approximation of human articular chondrocytes 
for various research purposes, including mouse embryonic fibroblasts [22] and rat chondrosarcoma 
cells [33]. One such cell line, ATDC5 cells, are sourced from teratocarcinoma fibroblasts from 
mice. These cells closely follow the differentiation pathway of human articular chondrocytes, and 
express the chondrocytic phenotype of type II collagen and aggrecan [34]. Additionally, they 
respond to transcription factors such as SOX9. ATDC5s also proliferate quickly, and expand in an 
undifferentiated form; these benefits, along with their close approximation of human articular 
chondrocytes, make them a good model for chondrocytic research [35].   
 
Role of SOX9 in Differentiation 
Bone morphogenetic proteins (BMPs), specifically BMP-2, have been shown to induce 
chondrogenesis in ATDC5 cells, promoting early differentiation as well as the increase in type X 
collagen seen in late differentiation to hypertrophy [36]. BMP-2 signaling activates two pathways: 
BMP-2/Smad, and BMP-2/p38, both of which alter SOX9 activities, levels, or both. The Smad 
pathway only affects SOX9 activity but does not alter mRNA content, while the p38 pathway 
affects both SOX9 activity and expression. BMP-2 stimulates transcription of SOX9 by increasing 
binding of the transcription activator NF-Y to the CCAAT region on the gene’s promotor [22]. 
Once BMP-2 increases SOX9 expression and activity, the SOX9 protein acts as a transcriptional 





under several categories, most notably genes encoding ECM proteins and those that regulate the 
ECM such as modifying enzymes, transporters, or receptors [37].  
 SOX9 levels are high during early differentiation and decrease as chondrocytes move 
towards hypertrophy, making temporal quantification of SOX9 particularly important. As SOX9 
begins to commit MSCs to a chondrocytic line, the cells first begin to condense. Cells that 
ultimately form the articular cartilage will begin producing dense ECM. Meanwhile, those of the 
growth plate proliferate and drop out of the cell cycle, differentiating into pre-hypertrophic 
chondrocytes which then increase in volume by almost 20 times, converting to hypertrophic 
chondrocytes. Eventually these hypertrophic chondrocytes calcify the ECM surrounding them, 
which osteoclasts degrade for osteoblasts to turn into bone matrix. Hypertrophic chondrocytes stop 
expressing SOX9 and begin expressing type X collagen rather than type II, as well as other 
hypertrophic markers like RUNX2. These terminally differentiated chondrocytes then die, or as 
some recent evidence suggests, may go on to further re-differentiate into osteoblasts [38]. 
Chondrocytes in the articular cartilage begin to undergo hypertrophy during OA disease 
progression [39], losing the phenotypic expression of type II collagen needed for healthy 
cartilaginous ECM. As type II collagen provides articular cartilage with its resistance to shear and 
tensile stress [32], SOX9 levels act not only as an indicator of the differentiation state of 
chondrocytes, but also as an indirect measure of their mechanical properties. 
 Additionally, SOX9 levels in OA are downregulated as compared to typical cartilage tissue 
[20], making the transcriptional activator a potential target for OA drugs, a treatment option which 
is currently lacking. Developing drugs is a costly process, with high rates of failure. The overall 





$985 million [41]. A good cellular model that appropriately mimics the in vivo environment can 
help prevent expensive attrition at later clinical trial stages, reducing costs and speeding up the 
development process. Given SOX9’s importance to the phenotype of chondrocytes, having a fast, 
simple, and non-destructive method of quantifying its expression could lead to great improvements 
in osteoarthritis treatment.  
 
Non-Destructive Luciferase-Based Reporting 
Luciferases, proteins which emit light in the presence of luciferins, are widely used. Their 
luminescence can be used for imaging or to quantify cellular properties by linking luminescence 
levels to a characteristic of interest such as promotor activity. Gaussia luciferase (Gluc) is a 
secreted luciferase; this means its levels can be quantified directly from media, making it very 
convenient for measuring cells in culture, particularly 3D spheroids [42]. Lentiviruses are 
pathogens which insert their genetic material into their hosts genome. While they cause a variety 
of serious diseases such as HIV, their ability to transport RNA from outside a cell into the nucleus 
and incorporate it into the existing genetic material makes them a useful tool in gene editing. 
Lentiviral vectors are based on HIV but separate the genes for infectivity and transfer of viral DNA 
onto different plasmids. This ensures that the vector can infect only a single cell and cannot 
propagate and spread, making it a safe method of gene transduction [43]. Using lentiviral 
transduction and Gluc, SOX9 levels can be quantified non-destructively by transducing cells with 
the gene for Gluc under the control of the SOX9 promotor. Under conditions in which the SOX9 
promotor is activated, Gluc is produced, allowing promotor activation to be easily quantified by 





 Several studies have successfully transduced SOX9 into various chondrocytic cell lines, 
and some work has been completed with non-destructive reporters [20, 30, 44]. While it was still 
ultimately a destructive assay, transduction of SOX9 tagged with green fluorescent protein and 
FLAG tags into human articular chondrocytes to increase those cell’s production of SOX9 was 
used to determine what genes SOX9 regulates [20]. In this case, the genes regulated were 
determined using an RNA hybridization microarray analysis [20]. Their expression levels were 
quantified with quantitative real time PCR, simply comparing expression levels in native tissue to 
tissue with SOX9 upregulated by its additional transduction into the cell [20]. A secreted luciferase 
reporter system for promotors of SOX9, aggrecan, and osteocalcin has also been transduced into 
bone marrow derived human mesenchymal stem cells (hBM-MSCs) to determine the effect of 
certain conditions on the differentiation of MSCs into chondrocytes [30]. As these probes do not 
require destruction of samples for quantification, they are well suited to studying the temporal 
changes that accompany differentiation [30]. The use of secreted luciferase reporters to assess the 
effect of culture conditions on chondrogenic properties has also been met with success. A 
luciferase reporter driven by type II collagen promoter was transduced into ATDC5 cells to 
determine optimal culture media components needed for improved production of type II collagen 
[44]. The use of this reporter allowed for high-throughput testing of a wide variety of media 
components in varying quantities [44]. These previous successes bode well for similar success 
with transducing a SOX9 promotor luciferase reporter into ATDC5’s and human articular 
chondrocytes for high-throughput screening applications.   
 With the widespread and increasing impacts of osteoarthritis, the need for improvements 





drawbacks including limitations in efficacy, scale, or longevity. Much work is being done in tissue 
engineering to grow enough cartilage tissue to resurface entire joints. However, this technology 
has several hurdles to surmount before it is a viable treatment, including that chondrocytes tend to 
de-differentiate as they are expanded in culture. Determining conditions for cell culture to support 
growth of chondrocytes that produce high quality ECM requires that the protein composition and 
mechanical properties of the experimental tissues be readily measurable. Historic measurement 
techniques give only a snapshot of current properties and require sample destruction, making them 
inadequate for the high-throughput methods necessary to quickly drive the field forward. The use 
of promotor-driven luciferase reporter cells to quantify the expression of certain key proteins in 
chondrocyte development has shown success for several applications already, allowing for 
temporal evaluation without sample destruction. As SOX9 is instrumental in the differentiation of 
chondrocytes, the development of a SOX9 reporter cell allows for improved testing of the effect 
of various culturing conditions on the molecular signature of chondrocytes. Additionally, as SOX9 
levels are reduced in osteoarthritis, transducing such a promotor into human articular chondrocytes 






CHAPTER TWO: PRODUCTION OF REPORTER CELLS 
Materials and Methods 
Preparation of Plasmid 
Use of lentiviral-based vectors for genetic editing has been made safer by separation of viral 
replication genes into several plasmids,  including the packaging plasmid psPAX2 (Plasmid 
#12260; Addgene), envelope gene plasmid pMD2G (Plasmid #12259; Addgene), and transgene 
plasmid, in this instance SOX9-gLuc (Fig 3; 9,405 bp, Genecopoeia). To generate the necessary 
quantity of plasmid for lentiviral production, competent E. coli (GCI-L3; Genecopoeia) were 
transformed with each of the three vectors individually. These E. coli were grown in LB media 
containing glycerol and ampicillin (0.4%), lysed, and the plasmid purified out using a commercial 
maxiprep kit (ZymoPURETM II Plasmid Maxiprep Kit; Zymo Research Corp). Plasmid 
purification and concentration was determined using a spectrophotometer (NanoDrop, 
ThermoFisher Scientific). Finally, confirmation of the plasmid was verified by running gel 
electrophoresis (0.7% w/v agarose in TBE) on both purified plasmid and plasmid linearized by 
restriction enzyme digest using BamH1 compared to a gene fragment ladder of known lengths 







To generate the lentiviral particles for transduction, HEK293Ta cells were transfected with the 3 
plasmids already grown and purified: pMD2G, psPAX2, and SOX9-gLuc, using calcium 
phosphate nanoparticles. Plasmids were combined in equimolar concentrations in HEPES buffered 
saline, then precipitated out while vortexing in calcium solution [45]. These nanoparticles were 
added to the cells and incubated overnight (37 ⁰C, 5% CO2). Media was then replaced the next day 
Figure 3: Plasmid Map for SOX9-gLuc 
The plasmid contains Gaussia luciferase under the control of the SOX9 promoter. 
Additionally, it contains a gene for ampicillin resistance to select for transformed 
E. coli, as well as a gene for puromycin resistance to select for transduced 






(after ~12 hours) with HEK293Ta growth media. The conditioned growth media containing the 
lentiviral particles was collected daily over 72 hours, and the lentiviral particles were concentrated 
through ultracentrifugation (15,000 RCF on a 10% sucrose gradient) [46]. Particles were serially 
diluted from 1x to 0.0001x concentrations.  
 
Cell Culture and Infection 
After the lentiviral particles were generated, concentrated, and serially diluted, they were added to 
ATDC5 cells in a 24-well plate (Corning Costar) in the presence of polybrene (4 µg/ml, EMD 
Millipore) to enhance infection. These cells were grown for two passages in puromycin to select 
for those that were transduced. Additionally, non-infected ATDC5 cells were grown in both 
standard and puromycin containing growth media (DMEM low glucose with 5% FBS and 1% 
pen/strep) to act as positive and negative controls. An initial evaluation of luminescence from 
media of all the cell lines determined which cells were significantly infected to establish the cell 
line to use in further applications. To evaluate luminescence, 50 µl of coelenterazine substrate mix 
[47] (BioLux® Gaussia Luciferase Assay Kit; New England BioLabs) were added to 20 µl media 
samples from cells exposed to each concentration of virus as well as non-infected ATDC5s by an 
OT-2 pipetting robot (Opentrons OT-2). Luminescence was recorded in relative light units by a 96 







Titration of Lentivirus 
Evaluation of lentiviral concentration was determined by extraction of viral RNA from 
concentrated media, cDNA synthesis using a commercial kit, and qRT-PCR on the purified RNA 
product compared to standards (Lenti-Pac HIV qRT-PCR Titration Kit, GeneCopoeia). The 
activity of particles generated was determined through a functional titer by serially diluting them 
before infecting ATDC5s. mRNA was extracted from ATDC5-gLuc cells using a commercial kit 
(PureLink RNA Mini Kit, Invitrogen), mRNA purity and concentration were evaluated using RNA 
ScreenTape (Agilent), and cDNA was synthesized normalized to mRNA concentration. qRT-PCR 
was run on RNA isolated from the cells to establish the effectiveness of infectivity, with primers 
designed to amplify murine SOX9, gLuc, and the reference genes HPRT and PPIA (Table 1). 









Table 1: Primers for qRT-PCR 
 Forward Primer Reverse Primer 
mSOX9 5’-GAGGAAGTCGGTGAAGAACGGA-3’ 5’- GTTTTGGGAGTGGTGGGTGG-3’ 
gLuc 5’-ACGCTGCCACACCTACGA-3’ 5’-CCTTGAACCCAGGAATCTCAGGAA-3’ 
mHPRT 5’-AAGTTTGTTGTTGGATATGCCC-3’ 5’-CTCATCTTAGGCTTTGTATTTGGC-3’ 





Results and Discussion 
Plasmid Purity and Concentration 
 
 
Nanodrop spectroscopy showed that the purification produced plasmid at a sufficient concentration 
and quantity for lentivirus production. As shown in Figure 5, digestion and gel electrophoresis of 
the plasmid gave bands that confirm the plasmid’s identity and showed it to be sufficiently pure.  
Figure 5: Plasmid Digested by BAMH1 and Run on 0.7% Agarose Gel 
From left to right: 1 kb gene ruler (Thermo Fisher Scientific), Col10A1-gLuc digested and undigested, OC-fLuc 
digested and undigested, SOX9-gLuc digested and undigested, pMD2.G digested and undigested, RunX2-gLuc 






Initial Luminescence Evaluation 
Of the ATDC5-gLuc cell lines infected with serially diluted lentivirus, only the 1x and 0.1x of 
virus generated on 6/16 and the 1x of virus generated on 6/15 had luminescence that was 
significantly greater than the non-infected ATDC5s. No upper concentration of virus resulted in 
cell death, indicating that viral titers were likely low.  
Figure 6: Luminescence Assay on Media from Newly Infected Cells 








The lentivirus qRT-PCR titer confirmed low titers, with neither lentivirus produced on 6/16 or 
6/15 falling within the range of lentivirus standards. Lentivirus standards fit the curve well, with 
an R2 of 0.96. The 6/16 virus had an average value of 42,188 particles/ml, while 6/15 had an 
average value of 945,313 particles/ml. While the qRT-PCR titer for the 6/15 standards was higher 
than that produced on 6/16, as they were both outside of the standard range this was inconclusive. 
Additionally, the absolute number of viral particles does not necessarily indicate the number that 
are infectious. This requires a functional titer e.g. with ATDC5 cells.  
Figure 7: Standard Curve for qRT-PCR Based Lentivirus Titer 






For the functional cell infection titer, normalized to reference genes and compared to the ATDC5-
gLuc sample of 6/15 1 x, the 6/15 1 x had a relative quantification (RQ) of 1.0 and the 6/16 1 x 
had a RQ of 0.797. The 6/16 0.1 x cells did not cross the threshold within 40 cycles. While qRT-
PCR titers showed a higher production of lentivirus on 6/15, the functional cell infection titers 
indicated that 6/15 and 6/16 1 x had much closer levels of infection than expected. Therefore, since 
the initial quantification of luminescence was much higher for 6/16 1 x cells and there was not a 







CHAPTER THREE: DOSE RESPONSE TO TGF-β1 
Materials and Methods 
Production of High-Density Pellets 
As they performed best in the initial evaluation of luminescence, cells from the 6/16 1x lentiviral 
cell line (ATDC5-gLuc) and non-infected ATDC5 cells were trypsinized, resuspended in basal 
chondrogenic media (Dulbecco’s modified Eagle’s medium high glucose supplemented with 
pen/strep, dexamethasone, ITS + premix, glutamax, pyruvate, MEM non-essential amino acids, 
ascorbate-2-phosphate, and fungizone [29, 44]), counted via hemocytometer, and seeded in a 96-
well non-adherent u-bottom plate (Greiner) at a cell density of 50,000 cells per well in 200 µl 
media. Only the inner wells were seeded with cells, while the outer wells were filled with PBS to 
ensure a consistent environment with limited media evaporation. Six rows containing six pellets 
each of both ATDC5-gLuc and non-infected ATDC5s were seeded across two plates. The plates 
were centrifuged (500 x g, 5 minutes) to initiate pellet formation and were then incubated at 
physiological oxygen tension (37 ⁰C, 5% CO2, 5% O2) to allow for pellet contraction. This was 
considered day 0. Transforming growth factor beta 1, or TGF-β1, is known to induce 
chondrogenesis and should therefore increase SOX9 promotor expression. Six different dilutions 
of TGF-β1 (10, 1, 0.5, 0.1, 0.05, and 0.01 ng/mL) in chondrogenic media were used to establish a 
dose-response curve between TGF-β1 and the luminescence values from luciferase assays on the 
growth media. The day after pellet formation, the basal chondrogenic media was replaced with 






Cell Feeding and Sampling 
Cells were fed and sampled every Monday, Wednesday, and Friday through day 21. 150 µl of old 
media were removed, 20 µl of which were placed in a white 96 well plate (Greiner Bio-One) for 
luminescence evaluation, as described in Chapter 2. 150 µl of new media was added back to each 
of the wells, and bright-field images of each pellet was taken with an ImageXpress Pico system 
(Molecular Devices). Pellet size was analyzed from the microscope images using ImageJ, first by 
applying a binary mask and then measuring total area, circularity, and solidity for each area larger 
than 1000 pixels. Luminescence of ATDC5-gLuc cells compared to non-infected ATDC5s for 
each condition and day was evaluated using multiple t-tests.   
Pellet Harvesting 
After sampling and imaging on day 21, pellets were harvested for end-of-experiment RNA analysis 
and histology. Five pellets were removed from media and placed in 300 µl of RNA lysis buffer 
(Purelink RNA Mini Kit, Invitrogen) containing β-mercapatoethanol. The pellets were 
homogenized, and the RNA was purified with a commercial kit using on-column DNase (PureLink 
RNA Mini Kit, Invitrogen). mRNA purity and concentration were evaluated using RNA 
ScreenTape (Agilent), and cDNA was synthesized for qRT-PCR evaluation. qRT-PCR (2x SYBR 
Green PCR mix, ThermoFisher Scientific) was run on each sample amplifying mSOX9 and gLuc 
and the reference genes mPPIA and mHPRT as described in Chapter 2. Each experimental 
condition was a single biological replicate of five pellets with two technical replicates. The final 
pellet was removed from media and placed in 300 µl of neutral buffered formalin for histology, 
and then transferred into PBS after 24 hours. Pellets were placed into square mesh cassettes and 





80 minutes in xylene, and paraffin for an hour (Leica ASP300S). Processed tissue was embedded 
in paraffin wax (Leica Biosystems Embedder) and left overnight at 4°C to harden before 
sectioning. Blocks were sectioned at 5 µm thick (Leica Biosystems RM2125 RTS), and sections 
were floated in a water bath at 50⁰C before being fixed to slides (VWR Superfrost) which were 
baked overnight at 40⁰C. Slides were deparaffinated and then stained with hematoxylin, Fast Green 
FCF, and Safranin-O. Coverslips were attached above the stained pellet sections with a resin 
mounting media (Cytoseal) which was allowed to dry overnight before imaging with an 








Results and Discussion 
Luminescence Assays 
 
The highest concentration,10 ng/ml TGF-β1 as shown in Figure 8A, was expected to have the 
strongest signal, since TGF-β1 induces chondrogenesis. While the first two timepoints had 
significant luminescence, beyond that the luminescence unexpectedly dropped off. This may be 
Figure 8: Luminescence of ATDC5-gLuc cells treated with TGF-β1 over 21 days 
Relative light values of ATDC5-gLuc and non-infected cells. * indicates p < 0.05 for multiple t-tests of ATDC5-
gLuc and non-infected. 






due to an increase in metabolism causing a drop in pH below luciferase’s optimal range, which 
was suggested by a difference in well color after the addition of substrate compared to samples 
containing less TGF-β1. The kit used for evaluation of luminescence uses a buffered solution, and 
so increasing the buffering capacity may improve luminescence readings for samples with high 
metabolic activity. This is especially possible for days where the ATDC5-gLuc cells had a 
luminescence significantly lower than background, such as days 7, 9, and 14. As shown for the 0.5 
and 0.01 ng/ml TGF-β1 (Figures 8 B and C), significant luminescence was seen as late as day 18, 
indicating that the signal was not transient, and that lower concentrations of TGF-β1 may shift the 
time period of chondrogenesis later. This shift in chondrogenesis with TGF-β1 dosage illustrates 
the potential for having non-destructive evaluation methods such as this for temporal analysis. 
However, with poor initial viral titers, the signal to background ratio is very low. Along with an 
improvement of the assay buffer, an additional round of lentiviral particle generation and improved 






 Day 9 (Figure 9A) had high luminescence of ATDC5-gLuc above non-infected ATDC5s 
for all conditions but 10 ng/mL which had already dropped off  by day 7. However, by day 21 
(Figure 9B), luminescence for ATDC5-gLuc was not significantly higher for any conditions and 
was in fact lower than non-infected for 0.5, 0.05, and 0.01 ng/mL. This may indicate that the pellets 
were reaching hypertrophy, as SOX9 levels decrease at this point. Further study could explore this 
possibility through qRT-PCR evaluation of hypertrophic markers such as osteocalcin.  
 Unfortunately, the time intervals between each sampling were not constant. This may have 
caused the inconsistency in background luminescence of non-infected cells. This lack of 
background consistency across days, combined with how luminescence is measured in relative 
light units which is specific to the plate reader rather than an absolute value, means that it is 
Figure 9: Luminescence of ATDC5-gLuc Cells on Day 9 and 21 
Relative light values of ATDC5-gLuc and non-infected cells. * indicates p < 0.05 for multiple t-tests of ATDC5-
gLuc and non-infected. 






difficult to compare luminescence between days on the same pellet. Consistency may be improved 
enough to allow for time point comparison by sampling at regular intervals.  
 
Pellet Size Evaluation 
 
 
Figure 10: TGF-β1 Pellet Images, Days 1 and 21 
A: ATDC5-gLuc cells B: Non-infected ATDC5s  







Both the ATDC5-gLuc and non-infected pellets started out with consistent sizing across TGF-β1 
dosage, but by day 21 there was a very clear pellet size dose-response to TGF-β1 (Figs. 10, 11, 
12). Pellet imaging indicated that infection did not alter the cells’ growth, as both ATDC5-gLuc 








Figure 11: TGF-β1 Pellet Size 
Area of ATDC5-gLuc and non-infected cells.  








The ATDC5 non-infected pellets seem to have been seeded initially at a lower density than the  
pellets, but they changed in size proportionally to the higher density ATDC5-gLuc pellets over 
time, further supporting that infection does not change pellet morphology. The 10 ng/ml pellets 
(Figure 11A) increased in size over time; as these cells were undergoing chondrogenesis, cell 
replication is arrested and so an increase in size is likely due to production of extra cellular matrix. 
This contrasts with the 0.01 ng/ml pellets (Figure 11B) which decreased in size over the first week 
before stabilizing. The initial size decrease may be a continuation of the initial contraction seen in 
the first 24 hours of culture before they reach their most dense at the end of the first week. By day 
21 (Figure 12), a dose-response of pellet size to TGF-β1 simulation was clear. As with the size 
change of the 10 ng/mL TGF-β1 over time, the differences of size with dose indicates increased 
production of ECM proteins with TGF-β1 dosage, and the identical response of ATDC5-gLuc to 
non-infected cells provides further evidence that infection did not significantly interfere with 
cellular growth.   
Figure 12: TGF-β1 Pellet Size on Day 21 Normalized to Day 1 








qRT-PCR showed a lack of SOX9 response to TGF-β1 dosage at harvest on day 21 (Figure 13), 
supporting the lack of dose-response in luminescence on day 21. While there were large variances 
in relative quantification between samples, there was no significant difference in expression 
between ATDC5-gLuc and non-infected cells. 
 
 
Figure 13: SOX9 Expression with TGF-β1 Dose 







Only ATDC5-gLuc cells showed expression of gLuc, further supporting infection and that signal 
was not transient (Figure 14). At harvest of pellets, the gLuc expression did not follow TGF-β1 
doseage, nor did it correlate well to luminescence at day 21. Additionally, gLuc expression did not 
correlate with SOX9 expression for the ATDC5-gLuc cells (Figure 15). However, as with the 
SOX9 expression, variance for gLuc relative quantification was quite high and so small differences 
between samples may be obscured by this. As mRNA extraction from cells grown in condensed 
Figure 14: gLuc Amplification Plot for ATDC5-gLuc and Non-infected Cells 






pellets is difficult and results in lower yeilds and purity than extraction from monolayer cells, 
lysing of more than five pellets may be necessary to generate sufficient mRNA yeild to reduce the 
variance. With this lack of correlation between the two, further work to establish the correlation 
will include reinfection of reporter cells with higher titer lentivirus to generate reporter cells with 
increased gLuc expression and higher signal to background. Additionally, cells will be grown in 
monolayer to facilitate mRNA extraction, and qRT-PCR will be completed at an earlier timepoint 
when SOX9 expression is still elevated.  
Figure 15: gLuc vs. SOX9 Expression 







Histological staining of pellets across the TGF-β1 dosage shows a change in proteoglycan content 
with dose (Figure 16). While the 10 and 1 ng/mL concentrations are similar in staining intensity, 
by 0.5 ng/mL there is a sharp drop off in proteoglycan content. This supports the usage of 1 ng/mL 
dosage in culturing media, as higher concentrations do not result in large increases in ECM protein 
production. It is expected that increasingly smaller dosages of TGF-β1 would have even less 
proteoglycans; however, these pellets had end sizes too small to effectively embed and section. 
Exploring the histological characteristics of pellets grown in these lower TGF-β1 concentrations 
would require seeding cells at a higher density upon pellet formation to generate larger pellets.  
 
Figure 16: ATDC5-gLuc Histology for TGF-β1 Dose-Response 






While differing in size, a comparison of ATDC5-gLuc and non-infected cells at both 10 and 0.5 
ng/mL show comparable staining patterns (Figure 17). This identical response offers even more 
evidence that infection did not appreciably change cell growth characteristics.   
Figure 17: ATDC5-gLuc vs. Non-Infected Histology 







CHAPTER FOUR: OPTIMIZED MEDIA COMPARISON 
Materials and Methods 
Media Generation 
Traditional defined chondrogenic media (i.e. media lacking undefined components such as fetal 
bovine serum) used for chondrocyte differentiation is lacking in several vitamins and minerals 
known to be necessary in chondrogenesis. This Traditional media is Dulbecco’s modified Eagle’s 
medium high glucose supplemented with pen/strep, dexamethasone, ITS + premix, glutamax, 
pyruvate, MEM non-essential amino acids, ascorbate-2-phosphate, and fungizone. This lab has 
postulated an Optimized media with components at levels shown to increase type II collagen 
promoter driven mRNA production individually [44]. The Optimized media uses Traditional 
media as a base, with 15 added vitamins and minerals that are found in vivo (chromium 28 pg/ml, 
cobalt 90 fg/mL, copper 6.7 ng/mL, iodine 92 pg/mL, manganese 12 pg/mL, molybdenum 0.2 
pg/mL, linolenic acid 27 ug/mL, retinoic acid 78 pg/mL, biotin 3 pg/mL, vitamin B12 914 pg/mL, 
vitamin D 8.6 fg/mL, vitamin K 11 ng/mL, zinc 120 pg/mL, and thyroxine 25 pg/mL). The 
vitamins and minerals were split into water soluble and ethanol soluble groups and a 2,000x stock 
of both groups was created. Optimized media was generated through addition of the 2,000x stocks 
to previously defined chondrogenic media while Traditional media was generated by adding 
equivalent volumes of ethanol and water as a control. Cells were split into two groups, receiving 
Traditional and Optimized media. Past studies have seeded pellets in traditional media on day 0 so 
that the first media change on day 1, post pellet contraction, is the point at which stimulation with 
vitamins and minerals occurs. To prevent aspiration of the pellet, only 75% of the media is 





media at 111% and 133% of the target vitamin and mineral concentration was generated to 
elucidate the effect of vitamin and mineral addition timing. Cells were split into two groups of 
those receiving vitamins on day 0 (D0) and those receiving vitamins on day 1 (D1). 
Cell Seeding, Feeding, and Sampling 
Cells from the 6/16 1x lentiviral cell line (ATDC5-SOX9gLuc), non-infected ATDC5 cells 
(ATDC5), and previously infected reporter cells for type II collagen (ATDC5-COL2gLuc) for use 
as a positive control in luciferase assessment were trypsinized, resuspended in traditional 
chondrogenic media, and counted via hemocytometer. The cells were diluted with additional 
traditional chondrogenic media to reach a cell density of 2.5 million cells/mL. 20 µl of cells 
(50,000 total) per well of each cell type were seeded into two columns of a 96-well non-adherent 
u-bottom plate (Greiner). Each column (6 pellets) received either 180 µl of 111% traditional or 
optimized media; these were considered D0 cells. An additional 2 columns of each cell type were 
seeded with 20 µl cell suspension and 180 µl of chondrogenic media; these were considered D1 
cells. On the following day, D0 cells were fed with 1x traditional or optimized media, while D1 
cells were fed with the 133% traditional or optimized medias to reach a final concentration of 
100%. This was considered day 1, and cells were fed, imaged, and assayed for luciferase every 
Monday, Wednesday, and Friday for 21 days as described in Chapter 3. At each subsequent 
feeding, both D0 and D1 cells received 1x optimized or traditional media. At the end of 21 days, 






Results and Discussion 
Luminescence Assays 
In this assay, for both Day 0 and Day 1 stimulated cells, luminescence levels for non-infected 
ATDC5s (Figure 18) were significantly higher for traditional media than for optimized media. 
This difference varied by up to 2000 RLUs on several days of the assay. Since these pellets were 
not infected, the difference is an intrinsic property of the media, indicating that one or more of 
the additives themselves lowered luminescence values. To account for this difference, 
luminescence for reporter cells was normalized to the background values for the non-infected 
ATDC5s in either traditional or optimized media.  
Figure 18: Luminescence of Non-Infected Cells Stimulated on Day 0 and 1 
Relative light values of non-infected cells. * indicates p < 0.05 for multiple t-tests of traditional and optimized 
media. 







For cells stimulated with vitamins, luminescence was significantly higher on some days for day 1 
addition than day 0 addition. Interestingly, despite 1x media being added to both conditions 
every day past day one, the days with a significant difference in luminescence for day 1 
stimulated cells occurred later on, with day 21 significantly higher for both SOX9 and type II 
collagen.   
 
 
Figure 19: Luminescence of ATDC5-gLuc in Optimized Media Added on Day 0 and Day 1 
Relative light values of ATDC5-gLuc cells normalized to non-infected. * indicates p < 0.05 for multiple t-tests of 
Day 0 and Day 1.  






Optimized media had a significantly higher luminescence on at least one day for both reporters 
stimulated with vitamins on both day 0 and day 1 (Figure 20), while only day 17 for the 
COL2A1 reporter stimulated on day 1 was significantly higher luminescence for traditional 
media over optimized. While these few days of increased luminescence for optimized media is 
Figure 20: Luminescence of ATDC5-gLuc Cells in Traditional and Optimized Media 
Relative light values of ATDC5-gLuc cells normalized to non-infected. * indicates p < 0.05 for multiple t-
tests of traditional and optimized media. 






not overwhelming evidence in its favor, it indicates a potential improvement above the 
traditional option which can be further validated with qRT-PCR and histology.   





Figure 21: Representative images of Day 0 and Day 1 vitamin pellets 
A: Day 0 Pellets B: Day 1 Pellets 
From left to right, Traditional (SOX9 reporter, COL2A1 reporter, ATDC5 control) and Optimized (SOX9 reporter, 







By day 21, there was no significant difference in pellet size between day 0 and day 1 for either 
traditional or optimized media (Figure 22). However, the pellets grown in traditional media from 
day 0 were statistically significantly larger than those grown in optimized media by day 21. This 
is contrary to luminescence signals indicating that type II collagen and SOX9 expression was 
higher for some days during growth in optimized media. As the Optimized media was adjusted 
for promotion of type II collagen, it is possible that it is not an ideal media for other ECM 
proteins such as aggrecan and other proteoglycans, leading to overall smaller pellets despite an 
increase in type II collagen production.  
Figure 22: Pellet Size on Day 21 






 Additionally, cells grown in optimized media formed small colonies besides the main 
pellet (Figure 21 A & B) which were not included in the size evaluations. These smaller colonies 
reveal an interesting effect of vitamin addition on pellet contraction and formation and are more 




Figure 23: SOX9 Expression for Traditional and Optimized Media 






While luminescence data indicated that Day 1 addition of media resulted in significantly higher 
luminescence than for Day 0, including on the last day of sampling, Day 0 addition showed 
higher RQ for SOX9 with qRT-PCR (Figure 23). Additionally, Optimized media had higher 
SOX9 expression than Traditional. However, as with the previous qRT-PCR data, pellets result 
in poor yield and quality mRNA upon lysis, leading to very large error ranges for qRT-PCR. In 
order to determine if there is an actual discrepancy between the luminescence and qRT-PCR 
data, improved mRNA yield through additional pellets may be necessary.  
Figure 24: gLuc Expression for ATDC5-gLuc and Non-infected Cells 






An evaluation of gLuc for TGF-β1 dose response pellets for ATDC5-gLuc and non-infected cells 
gave an amplification curve where only infected cells crossed the threshold value. However, for 
the growth media experiment, non-infected cell sample did cross the cycle threshold, albeit much 
later. This is concerning, as non-infected cells should not be expressing any gLuc. In part, the 
apparent expression of gLuc by non-infected cells may be due to a lower automatic cycle 
threshold being set by QuantStudio to accommodate the lower gLuc expression for the growth 
media experiments than TGF-β1. This lower threshold may not prevent primer-dimer formation 





















Figure 25: Day 0 vs Day 1 Traditional and Optimized Media Histology 
A: Traditional Media, Day 0. B: Optimized Media, Day 0. C: Traditional Media, Day 1. D: 






Histology did not reveal any clear differences in proteoglycan content between Day 0 and Day 1 
optimized media, nor between Day 1 Traditional and Optimized media (Figure 25).  Day 0 
Traditional media resulted in a pellet with different shape and staining than the rest. However, 
this is likely just a difference in pellet orientation during embedding. While the pellets appear 
spherical, they are actually cup shaped. The sections with a spherical shape were sectioned from 
the bottom up, while the kidney shaped section is a side view. Given this difference in 
orientation, it is difficult to attribute the difference any difference in staining to media conditions. 
The side view reveals a potential difference in proteoglycan expression throughout the pellet, as 
in Figure 25A, the most intense staining area occurs along the edge of the pellet on what would 
be the surface contacting the bottom of the wells. When sectioned from the bottom up, this 
intense band along the edge would manifest as a ring of strong staining around the outside of the 
pellet (Figures 25 B-D).  
 Infection rates and viral titers were low resulting in poor initial infection of cells, but 
despite poor transfection the luminescent signal was seen to be non-transient and infection did 
not result in obvious metabolic changes. A potential temporal shift in TGF-β1 stimulated 
chondrogenesis was seen at lower doses, highlighting the need for a non-destructive reporter, and 
a difference in SOX9 and COL2A1 expression with media type and vitamin addition time was 
observed. Both of these topics are prospective avenues of further investigation using an 
improved promotor-driven secreted luciferase reporter system. Reporter cell improvements will 
include increasing infection rates of cell through generation of additional lentivirus and 
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